US-based Avenzo Therapeutics has commenced the open-label Phase I/II trial of its cyclin-dependent kinase 4 (CDK4) selective ...

Now, nivolumab -- in combination with chemotherapy -- is indicated for the first-line treatment of adults with unresectable ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer.

LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...